Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

NCT02332590
completedphase_3

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

NCT02293902
terminatedphase_3

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
completedphase_2

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736
completedphase_2

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431

Clinical Trials (5)

Showing 5 of 5 trials
NCT02332590Phase 3

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Completed
NCT02293902Phase 3

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Completed
NCT01764997Phase 3

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Terminated
NCT01061736Phase 2

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

Completed
NCT01900431Phase 2

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Completed

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5